Free tool
FAERS Monitor: Dovonex
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020554 or its brand name (Dovonex, Calcipotriene). Reports on generic versions are filed under their own applications.
Reports
3,398
Serious
1,388
41% of reports
Hospitalization
485
Death reported
69
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective832
- psoriasis718
- diarrhoea210
- arthralgia200
- rash187
- nausea186
- pain182
- pruritus177
- off label use173
- headache169
- product use in unapproved indication156
- therapeutic product effect incomplete144
- fatigue142
- psoriatic arthropathy137
- product dose omission issue123
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 6 |
| 2005 | 10 |
| 2006 | 12 |
| 2007 | 16 |
| 2008 | 31 |
| 2009 | 21 |
| 2010 | 24 |
| 2011 | 6 |
| 2012 | 24 |
| 2013 | 49 |
| 2014 | 52 |
| 2015 | 130 |
| 2016 | 140 |
| 2017 | 164 |
| 2018 | 164 |
| 2019 | 235 |
| 2020 | 216 |
| 2021 | 225 |
| 2022 | 215 |
| 2023 | 942 |
| 2024 | 251 |
| 2025 | 263 |
| 2026 | 202 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,761 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| psoriasisSignal | 718 | 34.2 | 32.1 | 23,131 |
| psoriatic arthropathySignal | 137 | 21.0 | 17.8 | 2,580 |
| therapeutic product effect incompleteSignal | 144 | 12.6 | 10.7 | 1,522 |
| drug ineffectiveSignal | 832 | 3.9 | 3.7 | 1,918 |
| product use in unapproved indicationSignal | 156 | 3.9 | 3.3 | 337 |
| arthralgiaSignal | 200 | 3.0 | 2.6 | 266 |
| pruritusSignal | 177 | 2.9 | 2.5 | 215 |
| rashSignal | 187 | 2.7 | 2.3 | 195 |
| product dose omission issueSignal | 123 | 2.6 | 2.2 | 120 |
| diarrhoeaSignal | 210 | 2.0 | 1.8 | 110 |
| pain | 182 | 1.8 | 1.6 | 70 |
| headache | 169 | 1.7 | 1.4 | 46 |
| nausea | 186 | 1.5 | 1.3 | 27 |
| off label use | 173 | 1.2 | 1.1 | 7 |
| fatigue | 142 | 1.1 | 1.0 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.